Scribe Therapeutics (NASDAQ:SCTX) Raised to “Hold” at Zacks Research

Scribe Therapeutics (NASDAQ:SCTX) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research report issued on Tuesday, Zacks reports.

SCTX has been the subject of several other reports. Leerink Partners started coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 target price for the company. HC Wainwright began coverage on Scribe Therapeutics in a report on Monday. They set a “buy” rating and a $60.00 price target on the stock. Guggenheim started coverage on Scribe Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $50.00 price objective for the company. Wells Fargo & Company began coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Scribe Therapeutics to a “hold” rating in a research report on Saturday, August 1st. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.75.

Scribe Therapeutics Stock Performance

Shares of NASDAQ:SCTX opened at $30.90 on Tuesday. Scribe Therapeutics has a 52-week low of $17.31 and a 52-week high of $39.60.

Scribe Therapeutics (NASDAQ:SCTX) last announced its quarterly earnings results on Wednesday, September 2nd. The company reported ($3.84) EPS for the quarter, beating analysts’ consensus estimates of ($6.20) by $2.36. As a group, analysts forecast that Scribe Therapeutics will post -6.72 EPS for the current year.

Insider Activity

In other news, Director Behzad Aghazadeh bought 2,383,333 shares of the stock in a transaction that occurred on Friday, July 24th. The stock was acquired at an average price of $15.15 per share, with a total value of $36,107,494.95. Following the completion of the purchase, the director directly owned 3,080,983 shares of the company’s stock, valued at approximately $46,676,892.45. This represents a 341.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CFO David Parrot bought 2,666 shares of the company’s stock in a transaction that occurred on Thursday, July 23rd. The stock was purchased at an average price of $15.00 per share, for a total transaction of $39,990.00. Following the acquisition, the chief financial officer owned 1,333 shares of the company’s stock, valued at $19,995. This trade represents a -200.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 3,727,237 shares of company stock worth $56,291,746 over the last quarter.

Trending Headlines about Scribe Therapeutics

Here are the key news stories impacting Scribe Therapeutics this week:

• Positive Sentiment: Quarterly loss beat expectations: Scribe reported a second-quarter 2026 loss of $3.84 per share, significantly narrower than the $6.20 loss analysts expected. The earnings surprise may have improved sentiment toward the clinical-stage biotechnology company. Scribe Therapeutics earnings press release
• Positive Sentiment: Pipeline advanced into human testing: The company initiated the first-in-human Phase 1 trial of STX-1150, an ultra-long-acting LDL-cholesterol-lowering therapy using its ELXR epigenetic silencing technology. The treatment is designed to avoid permanent genetic changes, potentially strengthening Scribe’s cardiovascular disease pipeline. Scribe Therapeutics second-quarter results and corporate highlights
• Positive Sentiment: Non-dilutive support and financing improved runway: Scribe received more than $25 million from the California Institute for Regenerative Medicine to advance STX-1200 and STX-1400. In addition, its upsized IPO, including the underwriters’ full option exercise, and a private placement to Sanofi generated approximately $155.5 million in gross proceeds. Management said available funding should support operations into the first half of 2029. Scribe Therapeutics financing and financial results
• Positive Sentiment: Analyst coverage was bullish: HC Wainwright began coverage with a “Buy” rating and a $60 price target, well above the stock’s recent trading level. The firm projects continued losses but expects quarterly losses to narrow after 2026.
• Neutral Sentiment: Management also announced participation in upcoming investor conferences, which could provide additional visibility for Scribe’s technology and clinical programs but does not itself change the company’s fundamentals. Scribe Therapeutics investor conference announcement
• Negative Sentiment: Scribe remains unprofitable, with HC Wainwright forecasting a $6.72 per-share loss for fiscal 2026 and a $4.90 loss for fiscal 2027. Continued clinical spending and the recently issued equity could also create ongoing dilution and volatility risks.

Scribe Therapeutics Company Profile

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.